Medtronic's Hugo Wins FDA Clearance for General Surgery, With No Install Count or Trial Figures
Hardware / news
Medtronic's Hugo Wins FDA Clearance for General Surgery, With No Install Count or Trial Figures
The Nov. 17 clearance covers about 3.5 million U.S. operations a year, but Medtronic's release names no price, no systems installed and no study results.

Medtronic said on Nov. 17 that the FDA cleared its Hugo robotic-assisted surgery system for general surgery, a category the company puts at about 3.5 million U.S. operations a year. The announcement carries no installed-base count, no price and no trial figures.
The clearance is an expanded 510(k), according to Medtronic's release. It covers all upper abdominal general surgical procedures, with cholecystectomy, Roux-en-Y gastric bypass, ventral hernia and small bowel resection named as examples, plus two lower abdominal procedures: inguinal hernia and appendectomy. Medtronic said those procedures make up more than half of the soft-tissue procedures performed in the U.S. each year.
Hugo's route to general surgery, from 2022 to Nov. 17
Hugo reached this clearance in stages. The Robot Report says Medtronic received CE marking for general surgery in Europe in 2022 and used that clinical data in its U.S. submission. A U.S. hernia repair study met its safety and effectiveness endpoints, Medtronic announced in September 2025, and the FDA cleared urology in December 2025.
| Date | Event | Source |
|---|---|---|
| 2022 | CE marking for general surgery in Europe | The Robot Report |
| September 2025 | U.S. hernia study meets safety and effectiveness endpoints | The Robot Report |
| December 2025 | FDA clears Hugo for urology | The Robot Report |
| July 2026 | FDA authorizes J&J's Ottava for general surgery | MedTech Dive |
| Nov. 17, 2026 | FDA clears Hugo for general surgery | Medtronic |
What the announcement leaves out
Neither the release nor the two trade reports give a number of Hugo systems installed or hospitals using them. MedTech Dive reports only that Medtronic says a growing number of U.S. hospitals use the system. Rajit Kamal, general manager of robotic surgical technologies at Medtronic, said, in The Robot Report's account, that "access is our number one priority" and said access depends on cost, training and support. Medtronic is working with hospitals on financial value propositions, but no list price appears anywhere.
The study figures are missing too. The September 2025 hernia trial is described only as having met its endpoints, with no sample size or complication rate.
Medtronic does supply two volume claims, both its own. Hugo is on track to pass 50,000 procedures by the end of Medtronic's fiscal year, and Hugo procedure growth is more than twice that of the robotic surgery market. The 50,000 is a cumulative global count; the 3.5 million is an annual U.S. count. Divided naively, the first is about 1.4% of the second, which is why the pair says little about share. The growth claim gives no baseline, so a small base would produce the same ratio.
The competitors Hugo now shares general surgery with
MedTech Dive notes that the da Vinci system launched in 2000 and that Hugo is the first large medtech soft-tissue robotic platform to reach the U.S. market since. Johnson & Johnson's Ottava received FDA authorization for general surgery in July, four months before Hugo. The report adds that Stryker agreed in October to distribute CMR Surgical's Versius soft-tissue robot in the U.S.
Medtronic is also hedging on hardware. In September it invested $700 million in Cornerstone Robotics and took rights to distribute Cornerstone's Sentire system in select markets outside the U.S., The Robot Report says. Disclosure habits differ across the sector: Rockwell's purchase of AGILOX came with a 2,500-robot field count and no price, while Medtronic offers a procedure target and no count. Regulators also set the pace for deployed machines, as California's freeway ban on Waymo showed on a different kind of robot.
What to watch next
Medtronic holds an investigational device exemption for a U.S. general surgery trial and is running an IDE study in gynecology covering radical, modified radical and total hysterectomies. A gynecology clearance would be the next U.S. indication to track. Medtronic's case for Hugo rests on what Matt Anderson, senior vice president and president of Medtronic's Surgical business, called a "practical option to help hospitals address capacity and access challenges", and capacity claims are checkable only once Medtronic publishes how many systems are installed.
Sources
More in Hardware
- 01Agility's Digit 5 Weighs Over 120 kg and Runs 90 Minutes a Charge, but No Source Gives a Digit CountThe first public pure-play U.S. humanoid maker reports $300 million in preorders, while its co-founder's own specs imply about 18 hours of motion in a 20-hour shift.
- 02Agent-Built FPGA Runs a Ternary LLM at 213 Tokens a Second, Beating Rented CPUs per Dollar but Not a T4Ankit Gupta spent about $10,000 in model tokens on an AWS F2 design; his own numbers fall to 76 tokens a second at 8,000-token context.
- 03Rockwell Buys AGILOX, Which Has 2,500 Robots in the Field, at an Undisclosed PriceRockwell says the deal more than doubles its AMR business and closes in fiscal Q2 2027; the last comparable purchase, Clearpath, was valued at $609 million.
- 04California Bars Waymo From Freeways After Three Cars Entered a US-101 Closure, Months After a 3,900-Car RecallThe DMV order took effect November 11. Neither report says whether the cars on 101 had the software Waymo recalled in June.